Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 10/20 | 0.34 |
| ▸ | HTR7 | P34969 | 10/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21401377 | 0.90 | KDM1A (0.46) | KDM1ASLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL2621574 | 0.84 | KDM1A (0.46) | KDM1ANPC1HTR1AHTR7 | |
| SCHEMBL18539746 | 0.81 | CYP2D6 (0.40) | KDM1ANPC1HTR1AHTR7 | |
| SCHEMBL20463166 | 0.80 | KDM1A (0.49) | KDM1ASLC6A2SLC6A4SLC6A3WNT1 | |
| SCHEMBL20812543 | 0.80 | KCNH2 (0.41) | KDM1ASLC6A2SLC6A4SLC6A3NPC1 | |
| SCHEMBL22924215 | 0.78 | KDM1A (0.46) | KDM1ASLC6A2SLC6A4SLC6A3WNT1 | |
| SCHEMBL26412504 | 0.78 | PABPC1 (0.44) | DRD2 | |
| SCHEMBL9911333 | 0.78 | CARM1 (0.47) | KDM1A | |
| SCHEMBL25467851 | 0.78 | KDM1A (0.46) | KDM1ASLC6A2SLC6A4SLC6A3WNT1 | |
| SCHEMBL25938964 | 0.78 | KDM1A (0.47) | KDM1ASLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | KDM1A 1877/4885SLC6A2 4719/4885SLC6A4 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.